Novan Inc NOVN shares are trading higher by 59% at $14.37 Friday morning after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primary endpoint and no serious adverse events were reported.
See Also: A Technical Look At Novan's Stock Amid 80% Spike
Novan is a clinical-stage biotechnology company that provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases.
Novan's clinical-stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
